Literature DB >> 16433787

Effects of monomethylfumarate on dendritic cell differentiation.

N H R Litjens1, M Rademaker, B Ravensbergen, H B Thio, J T van Dissel, P H Nibbering.   

Abstract

BACKGROUND: Fumaric acid esters (FAE) are effective against psoriasis vulgaris and monomethylfumarate (MMF) is believed to be the most bioactive metabolite of this medication. Earlier we found that the beneficial effects of FAE medication are accompanied by a downregulation of type 1 cytokine production by T-helper (Th) lymphocytes, which are important as they maintain a type 1 cytokine [interferon (IFN)-gamma, interleukin (IL)-2] environment in the skin lesions of psoriasis vulgaris patients and once maximal beneficial effects are obtained type 2 cytokine production is also decreased. In vitro MMF selectively induced type 2 cytokine production by primed Th lymphocytes, whereas type 1 cytokine production by and profileration of T lymphocytes were unaffected.
OBJECTIVES: As dendritic cells (DCs) present in these skin lesions play a key role in the activation of Th lymphocytes, we investigated the effects of MMF on monocyte-derived DC differentiation.
METHODS: Monocytes were differentiated into immature (i) DCs by cytokines with or without MMF. To establish whether these cells were differentiated into iDCs, we analysed the expression of cell surface molecules on these cells and the capacity to capture antigens using flow cytometry. Next, we determined whether these MMF-incubated (MMF-)iDCs could be matured by lipopolysaccharide (LPS) and whether MMF affected this responsiveness as well. For this purpose we measured cytokine production by these LPS-stimulated cells (MMF-DCs) using enzyme-linked immunosorbent assays as well as their ability to activate naive Th lymphocytes.
RESULTS: The presence of MMF during the differentiation of monocytes into iDCs resulted in cells that retained low levels of CD14 and hardly expressed CD1a. Upon maturation, these MMF-iDCs upregulated CD83 and costimulatory molecules and HLA-DR on their surface, indicating that these cells respond to LPS, albeit less than control iDCs. In addition, in response to LPS, MMF-iDCs did not decrease the capacity to capture antigens when compared with control iDCs. MMF-DCs hardly produced IL-12p70 and IL-10 and low levels of tumour necrosis factor (TNF)-alpha, whereas IL-8 produced by MMF-DCs and control DCs did not differ. Moreover, MMF-DCs were less able to induce IFN-gamma production by naive Th lymphocytes compared with control DCs. The production of IL-4 and IL-10 by naive Th lymphocytes cocultured with MMF-DCs did not differ from that by T cells cocultured with control DCs.
CONCLUSIONS: MMF inhibited the monocyte-derived DC differentiation resulting in cells that cannot be appropriately matured to DCs. Consequently, these MMF-DCs are less effective than control DCs in stimulating type 1 cytokine, but not type 2 cytokine production, in Th lymphocytes. This general immunomodulatory effect may in part explain the beneficial effects of FAE therapy in psoriasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433787     DOI: 10.1111/j.1365-2133.2005.07002.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  13 in total

Review 1.  Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.

Authors:  Roberto Bomprezzi
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

2.  Effect of herbal cream containing Fumaria officinalis and silymarin for treatment of eczema: A randomized double-blind controlled clinical trial.

Authors:  Fariba Iraji; Behzad Sharif Makhmalzadeh; Mahya Abedini; Ali Aghaei; Amir Siahpoush
Journal:  Avicenna J Phytomed       Date:  2022 Mar-Apr

Review 3.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 4.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

5.  The effects of fumaria parviflora L extract on chronic hand eczema: a randomized double-blind placebo controlled clinical trial.

Authors:  F Jowkar; A Jamshidzadeh; A Mirzadeh Yazdi; M Pasalar
Journal:  Iran Red Crescent Med J       Date:  2011-11-01       Impact factor: 0.611

Review 6.  Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes.

Authors:  Angelo Aquino; Grazia Graziani; Ornella Franzese; Salvatore P Prete; Enzo Bonmassar; Laura Bonmassar; Stefania D'Atri
Journal:  Clin Dev Immunol       Date:  2011-03-22

Review 7.  Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases.

Authors:  Zaidoon Al-Jaderi; Azzam A Maghazachi
Journal:  Front Immunol       Date:  2016-07-22       Impact factor: 7.561

8.  Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells.

Authors:  Anna Hammer; Anne Waschbisch; Ilka Knippertz; Elisabeth Zinser; Johannes Berg; Stefanie Jörg; Kristina Kuhbandner; Christina David; Jingbo Pi; Antonios Bayas; De-Hyung Lee; Aiden Haghikia; Ralf Gold; Alexander Steinkasserer; Ralf A Linker
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

9.  Fumaric acid esters in dermatology.

Authors:  Uwe Wollina
Journal:  Indian Dermatol Online J       Date:  2011-07

10.  Vitamin D₃ and monomethyl fumarate enhance natural killer cell lysis of dendritic cells and ameliorate the clinical score in mice suffering from experimental autoimmune encephalomyelitis.

Authors:  Zaidoon Al-Jaderi; Azzam A Maghazachi
Journal:  Toxins (Basel)       Date:  2015-11-13       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.